Literature DB >> 9687421

Molecular characterization of a TEM-21 beta-lactamase in a clinical isolate of Morganella morganii.

F Tessier1, C Arpin, A Allery, C Quentin.   

Abstract

A clinical isolate of Morganella morganii, with reduced susceptibility to expanded-spectrum cephalosporins and aztreonam, was found to produce an extended-spectrum beta-lactamase with a pI of 6.4. The nucleotide sequence of the encoding gene was that of the gene encoding TEM-21. This is the first molecular characterization of an extended-spectrum beta-lactamase in M. morganii.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9687421      PMCID： PMC105882     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Two novel transferable extended-spectrum beta-lactamases from Klebsiella pneumoniae in Tunisia.

Authors:  S Ben Redjeb; G Fournier; C Mabilat; A Ben Hassen; A Philippon
Journal:  FEMS Microbiol Lett       Date:  1990-01-15       Impact factor: 2.742

2.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

3.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

4.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

5.  Genetic and biochemical basis of resistance of Enterobacteriaceae to beta-lactam antibiotics.

Authors:  B Wiedemann
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

6.  Beta-lactamases: determination of their isoelectric points.

Authors:  M Barthelemy; M Guionie; R Labia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

7.  Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii.

Authors:  Y J Yang; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

8.  Properties of cephalosporinase from Proteus morganii.

Authors:  M Toda; M Inoue; S Mitsuhashi
Journal:  J Antibiot (Tokyo)       Date:  1981-11       Impact factor: 2.649

9.  Chronic Morganella morganii arthritis in an elderly patient.

Authors:  R S Schonwetter; F M Orson
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

10.  Proteus morgani is less frequently associated with urinary tract infections than Proteus mirabilis--an explanation.

Authors:  B W Senior
Journal:  J Med Microbiol       Date:  1983-08       Impact factor: 2.472
View more
  11 in total

1.  Characterization of TEM-56, a novel beta-lactamase produced by a Klebsiella pneumoniae clinical isolate.

Authors:  C Neuwirth; R Labia; E Siebor; A Pechinot; S Madec; E B Chaibi; A Kazmierczak
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Sequences of the genes for the TEM-20, TEM-21, TEM-22, and TEM-29 extended-spectrum beta-lactamases.

Authors:  G Arlet; S Goussard; P Courvalin; A Philippon
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Clinical strain of Pseudomonas aeruginosa carrying a bla(TEM-21) gene located on a chromosomal interrupted TnA type transposon.

Authors:  Véronique Dubois; Corinne Arpin; Patrick Noury; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.

Authors:  Corinne Arpin; Laure Coulange; Véronique Dubois; Catherine André; Isabelle Fischer; Sophie Fourmaux; Frédéric Grobost; Jacqueline Jullin; Brigitte Dutilh; Jean-Francois Couture; Patrick Noury; Isabelle Lagrange; Aline Ducastaing; Henri-Pierre Doermann; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

6.  Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.

Authors:  Corinne Arpin; Véronique Dubois; Jeanne Maugein; Jacqueline Jullin; Brigitte Dutilh; Jean-Philippe Brochet; Gilberte Larribet; Isabelle Fischer; Claudine Quentin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

7.  Molecular characterization of a ceftazidime-resistant Morganella morganii isolate producing a TEM-10 beta-lactamase.

Authors:  H Barroso; A Freitas-Vieira; A Duarte
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  Prolonged outbreak of infection due to TEM-21-producing strains of Pseudomonas aeruginosa and enterobacteria in a nursing home.

Authors:  Véronique Dubois; Corinne Arpin; Patrick Noury; Catherine Andre; Laure Coulange; Claudine Quentin
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

9.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers.

Authors:  Corinne Arpin; Véronique Dubois; Laure Coulange; Catherine André; Isabelle Fischer; Patrick Noury; Frédéric Grobost; Jean-Philippe Brochet; Jacqueline Jullin; Brigitte Dutilh; Gilberte Larribet; Isabelle Lagrange; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

10.  Clinical manifestations and prognostic factors of Morganella morganii bacteremia.

Authors:  T-Y Lin; M-C Chan; Y-S Yang; Y Lee; K-M Yeh; J-C Lin; F-Y Chang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-09       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.